• AstraZeneca's new precision biologic gets FDA approval to treat severe eosinophilic asthma

    One year ago - By News Medical

    AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
    Read more ...


  • Vraylar receives FDA approval for maintenance schizophrenia treatment

    One year ago - By Healio

    Allergan recently announced that the FDA approved a supplemental New Drug Application for Vraylar for maintenance treatment of schizophrenia.
    “Schizophrenia is one of the most challenging mental health disorders to manage - particularly due to the complexity of patient symptoms, varying response to treatment and high rates of relapse,” Herbert Meltzer, MD, of Northwestern Feinberg School of Medicine, said in a press release. “The goal of clinicians is to minimize relapses, which can cause significant personal distress, and can often have serious implications for a patient's
    Read more ...